Should a correction insulin regimen be used instead of a regular insulin sliding‑scale for managing hyperglycemia?

Correction Insulin vs Regular Sliding Scale

Use a basal-bolus insulin regimen (scheduled basal insulin plus prandial insulin with correction doses) instead of sliding scale insulin alone for hospitalized patients with type 2 diabetes who have good nutritional intake—sliding scale insulin as monotherapy is strongly discouraged and should be abandoned. 1, 2

The Evidence Against Sliding Scale Insulin Alone

Sliding scale insulin (SSI) has been condemned in clinical guidelines for nearly two decades, yet remains widely used despite clear evidence of inferiority 2. The fundamental problem is that SSI is a reactive approach—it treats hyperglycemia after it has already occurred rather than preventing it 3. This leads to:

• Poor glycemic control: Mean blood glucose levels are 14.8 mg/dL (0.8 mmol/L) higher with SSI compared to basal-bolus regimens 4
• More hyperglycemic events: Meta-analysis shows significantly increased incidence of hyperglycemia with SSI 5
• Worse clinical outcomes: Only 38% of patients on SSI achieved glycemic control (mean glucose <140 mg/dL) versus 68% on basal-bolus insulin 3
• Increased complications: Basal-bolus approaches reduce composite outcomes including postoperative infections, pneumonia, bacteremia, and acute renal/respiratory failure 2

The Right Approach: Context-Dependent Insulin Strategies

For Type 2 Diabetes Patients with Good Oral Intake:

Use basal-bolus insulin 1, 2:

• Basal component: Long-acting insulin (glargine or detemir) once or twice daily
• Prandial component: Rapid-acting insulin (aspart, lispro, or glulisine) before each meal
• Correction component: Additional rapid-acting insulin for premeal hyperglycemia
• Dosing: Start with 0.3-0.5 units/kg/day total daily dose, split 50% basal and 50% prandial (divided three times daily) 2

For Patients with Poor Oral Intake or NPO Status:

Use basal-plus regimen 1, 2:

• Single dose of basal insulin (0.1-0.25 units/kg/day)
• Correction doses of rapid-acting insulin every 6 hours or before meals if eating
• This is the preferred approach for fasting patients or those undergoing procedures 2

Limited Acceptable Uses of SSI Alone:

SSI alone may be appropriate only for 2:

• Patients without diabetes who have mild stress hyperglycemia
• Patients with type 2 diabetes with good metabolic control on oral agents at home who develop mild hyperglycemia
• Never use SSI alone in type 1 diabetes—these patients always require basal insulin even when NPO 6

Critical Hypoglycemia Consideration

While basal-bolus regimens provide superior glycemic control, they carry a 4-6 times higher risk of hypoglycemia compared to SSI (RR 5.75 for glucose ≤70 mg/dL; RR 4.21 for glucose ≤60 mg/dL) 2. However, the incidence of severe hypoglycemia remains low in controlled settings (2.4% in basal-bolus groups versus 0% in SSI groups) 4.

To mitigate hypoglycemia risk:

• Use lower doses (0.1-0.25 units/kg/day) in high-risk patients: age >65 years, renal failure, poor oral intake 2
• Reduce home insulin doses by 20% if patient was on ≥0.6 units/kg/day at home 2
• Implement hospital-wide hypoglycemia protocols with treatment for glucose <70 mg/dL 1, 6
• Review treatment plans whenever glucose drops below 70 mg/dL 6

Practical Implementation

Correction insulin is not the same as sliding scale insulin alone. Correction doses are an adjunct to scheduled basal and prandial insulin, used to fine-tune control and adjust for unexpected hyperglycemia 3. When correction doses are frequently needed, increase the scheduled insulin doses rather than continuing to rely on corrections 3.

Common pitfall: The most recent evidence 7 shows that among patients already on optimal basal-bolus regimens, aggressive correction for glucose >140 mg/dL versus >260 mg/dL provides no additional benefit. This means once you have appropriate basal-bolus dosing established, you can use a less intensive correction threshold (>260 mg/dL) without compromising control, potentially reducing hypoglycemia risk and nursing workload.

Target glucose range: 140-180 mg/dL for most non-critically ill hospitalized patients 1, 3, 8.